Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec;7(Suppl 4):S358-S361.
doi: 10.21037/tlcr.2018.10.03.

Tumor mutational burden as predictive factor of response to immunotherapy

Maria Gonzalez-Cao  1 , Santiago Viteri  1   2 , Niki Karachaliou  3 , Andres Aguilar  1 , Juan Jose García-Mosquera  1 , Rafael Rosell  1   2   3   4
Affiliations
Editorial

Tumor mutational burden as predictive factor of response to immunotherapy

Maria Gonzalez-Cao et al. Transl Lung Cancer Res. 2018 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Santiago Viteri received advisory honoraria and travel expenses paid by Roche; speaker honoraria paid by BMS. Maria Gonzalez-Cao received advisory honoraria paid by Pierre Fabre, BMS; travel expenses paid by Pierre Fabre, BMS, Roche; speaker honoraria paid by BMS, AZ. The other authors have no conflicts of interest to declare.

Comment on

  • Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
    Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, Chaft JE, Voss MH, Tenet M, Li XM, Covello K, Renninger A, Vitazka P, Geese WJ, Borghaei H, Rudin CM, Antonia SJ, Swanton C, Hammerbacher J, Merghoub T, McGranahan N, Snyder A, Wolchok JD. Hellmann MD, et al. Cancer Cell. 2018 May 14;33(5):843-852.e4. doi: 10.1016/j.ccell.2018.03.018. Epub 2018 Apr 12. Cancer Cell. 2018. PMID: 29657128 Free PMC article.

References

    1. Hellmann MD, Nathanson T, Rizvi H, et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 2018;33:843-52.e4. 10.1016/j.ccell.2018.03.018 - DOI - PMC - PubMed
    1. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018;378:2093-104. 10.1056/NEJMoa1801946 - DOI - PMC - PubMed
    1. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-8. 10.1038/nature12213 - DOI - PMC - PubMed
    1. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99. 10.1056/NEJMoa1406498 - DOI - PMC - PubMed
    1. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8. 10.1126/science.aaa1348 - DOI - PMC - PubMed